Veru Inc.
Veru Inc. (Nasdaq: VERU) is a clinical-stage biopharmaceutical company developing medicines for cardiometabolic and inflammatory diseases. Its pipeline centers on enobosarm, an oral selective androgen receptor modulator being developed to preserve muscle and physical function while increasing fat loss in people with… From the company’s description.
In fiscal 2025, Veru Inc. reported a net loss of $22.73M. Operations used $30.00M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Veru Inc. does
In the company’s own words
Veru Inc. (Nasdaq: VERU) is a clinical-stage biopharmaceutical company developing medicines for cardiometabolic and inflammatory diseases. Its pipeline centers on enobosarm, an oral selective androgen receptor modulator being developed to preserve muscle and physical function while increasing fat loss in people with obesity taking GLP-1 receptor agonists, and sabizabulin, an oral microtubule disruptor being explored to reduce inflammation associated with atherosclerotic cardiovascular disease. Enobosarm has completed a Phase 2b study, and the company plans a further Phase 2b trial; sabizabulin is planned for a Phase 2 proof-of-concept study. Veru sold its FDA-approved FC2 Female Condom business in December 2024, ending its commercial product operations and leaving drug development as its focus. The company evolved from The Female Health Company, which acquired drug developer Aspen Park Pharmaceuticals in 2016 and adopted the Veru name in 2017. Veru reports no commercial revenue from its current products, which remain in development. Its website is www.verupharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- MIAMI, FL
- Fiscal year end
- September
- CIK
- 863894
- SIC
- 2834
Financial performance, year by year
Fiscal 2012–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Veru Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Veru Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Veru Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Veru Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Veru Inc.'s last four quarterly filings that the numbers alone won't show?”